[Clinical application of aldose reductase inhibitors--prevention and therapy of diabetic complications].
D000449:Aldehyde Reductase / Q000037:antagonists & inhibitors* / Q000378:metabolism; D001786:Blood Glucose / Q000378:metabolism; D048909:Diabetes Complications; D003920:Diabetes Mellitus / Q000378:metabolism; D003928:Diabetic Nephropathies / Q000188:drug therapy* / Q000517:prevention & control; D003929:Diabetic Neuropathies / Q000188:drug therapy* / Q000517:prevention & control; D003930:Diabetic Retinopathy / Q000188:drug therapy* / Q000517:prevention & control; D006801:Humans; D007093:Imidazoles / Q000493:pharmacokinetics / Q000627:therapeutic use; D048289:Imidazolidines; D007064:L-Iditol 2-Dehydrogenase / Q000378:metabolism; D009281:Naphthalenes / Q000627:therapeutic use; D010793:Phthalazines / Q000627:therapeutic use; D013401:Sugar Alcohol Dehydrogenases / Q000037:antagonists & inhibitors*
D001786:Blood Glucose; D007093:Imidazoles; D048289:Imidazolidines; D009281:Naphthalenes; D010793:Phthalazines; C040550:tolrestat; C042829:ponalrestat; C037070:M 79175; D013401:Sugar Alcohol Dehydrogenases; D007064:L-Iditol 2-Dehydrogenase; D000449:Aldehyde Reductase; C026411:sorbinil